GlassScriptPhysician profile
Diane George
NPI 1811130123
$16,424.89
in general payments reported to CMS, 2019-2025
32 companies · $7,633 in 2025
The $7,633 reported for 2025 was more than what 89% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $74.18 · 2021: $48.45 · 2022: $6,459 · 2023: $461 · 2024: $850 · 2025: $7,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,420 · Food and Beverage: $4,379 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,420.00 |
| Food and Beverage | $4,379.24 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $9,554.61 | 2019-2025 | Tremfya, Simponi Aria |
| Sobi, INC | $2,204.03 | 2025 | |
| Amgen INC. | $1,164.02 | 2019-2025 | Otezla, Krystexxa, Evenity |
| Abbvie INC. | $526.11 | 2019-2025 | |
| Ucb, INC. | $509.91 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $450.30 | 2019-2025 | |
| Pfizer INC. | $367.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $231.59 | 2023-2025 | Saphnelo, Fasenra |
| E.R. Squibb & Sons, L.L.C. | $222.77 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $218.06 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $127.98 | 2019-2022 | |
| Lilly USA, LLC | $122.53 | 2024-2025 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $115.56 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $99.48 | 2025 | Acthar |
| Janssen Scientific Affairs, LLC | $98.33 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $70.05 | 2023-2025 | Tymlos |
| Organon LLC | $37.86 | 2022-2025 | |
| Abbott Laboratories | $32.16 | 2022 | |
| Mallinckrodt Enterprises LLC | $29.99 | 2019 | |
| Invivyd INC | $27.82 | 2025 | Pemgarda |
| Novo Nordisk INC | $26.58 | 2023 | Ozempic, Rybelsus |
| Mylan Institutional INC. | $24.95 | 2023 | Hulio |
| Boston Scientific Corporation | $21.10 | 2025 | Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $20.83 | 2025 | Strensiq |
| Kiniksa Pharmaceuticals, LTD. | $20.56 | 2023 | Arcalyst |
| Fidia Pharma USA INC. | $16.09 | 2025 | Triluron, Hymovis |
| Scilex Pharmaceuticals INC. | $15.78 | 2025 | |
| Genentech USA, INC. | $15.75 | 2025 | Actemra |
| Zimmer Biomet Holdings, INC. | $14.88 | 2025 | Rosa |
| Idorsia Pharmaceuticals US INC | $13.65 | 2024 | Quviviq |
| Zyla Life Sciences, INC. | $12.16 | 2019 | |
| Medexus Pharma, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.